Garmin Set to Join the S&P 500; R.R. Donnelly & Sons to Join S&P MidCap 400 /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a...
Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li...
Valeant Pharmaceuticals Announces New Management Appointments /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_...
Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } l...
SCOTTSDALE, Ariz., Sept. 21, 2012 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that the Company's Board of Directors declared a quarter-end cash dividend of $0.10 per issued and...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medicis Pharmaceutical Corporation (“Medicis” or the...
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Medicis Pharmaceutical Corp. (“Medicis” or...
Valeant Pharmaceuticals To Syndicate Incremental Loans PR Newswire MONTREAL, Sept. 14, 2012 MONTREAL, Sept. 14, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX...
Valeant Pharmaceuticals Announces Management Change PR Newswire MONTREAL, Sept. 13, 2012 MONTREAL, Sept. 13, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX:...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Medicis Pharmaceutical Corporation (“Medicis” or the...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales